Paid Clinical Trials Yuma
Discover 15 paid clinical trials in Yuma, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Fianlimab & CemiplimabA Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Sponsor:
Regeneron Pharmaceuticals
Location:
Code:
NCT05800015
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
fianlimab
cemiplimab
Pemetrexed
Paclitaxel
Carboplatin
GSK3862995BA Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Sponsor:
GlaxoSmithKline
Location:
Code:
NCT06154837
Conditions
Pulmonary Disease, Chronic Obstructive
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
Interventions
GSK3862995B
Placebo
IanalumabStudy of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT05653349
Conditions
Primary Immune Thrombocytopenia (ITP)
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Ianalumab
Placebo
Corticosteroids
Observational StudyUnidos: Linking Individuals to Social Determinant and Community Health Services
Sponsor:
University of Arizona
Location:
Code:
NCT04124224
Conditions
Chronic Disease
Community Health Workers
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Accepted
Interventions
Unidos
ALTO-100ALTO-100 in Bipolar Disorder With Depression (BD-D)
Sponsor:
Alto Neuroscience
Location:
Code:
NCT06656416
Conditions
Bipolar Disorder I or II With a Major Depressive Episode
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
ALTO-100
Placebo
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Telisotuzumab Vedotin vs. DocetaxelA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Sponsor:
AbbVie
Location:
Code:
NCT04928846
Conditions
Non Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Telisotuzumab Vedotin
Docetaxel
Fianlimab & CemiplimabA Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor:
Regeneron Pharmaceuticals
Location:
Code:
NCT05785767
Conditions
Advanced Non-Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
fianlimab
cemiplimab
Placebo
CT-388A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Sponsor:
Carmot Therapeutics, Inc.
Location:
Code:
NCT06628362
Conditions
Overweight or Obese
Type 2 Diabetes Mellitus (T2DM)
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
CT-388
AbeLacimabStudy to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Sponsor:
Anthos Therapeutics, Inc.
Location:
Code:
NCT05712200
Conditions
Atrial Fibrillation (AF)
Eligibility Criteria
Sex: All
Age: 65+
Healthy Volunteers: Not accepted
Interventions
Abelacimab
Placebo